Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 4
1963 1
1982 1
1985 7
1986 5
1987 9
1988 14
1989 17
1990 34
1991 35
1992 52
1993 94
1994 131
1995 231
1996 375
1997 530
1998 700
1999 932
2000 1034
2001 1280
2002 1339
2003 1558
2004 1677
2005 1605
2006 1345
2007 1537
2008 1613
2009 1669
2010 1940
2011 2049
2012 2106
2013 1907
2014 1855
2015 1839
2016 1605
2017 1430
2018 1291
2019 532
2020 11
Text availability
Article attribute
Article type
Publication date

Search Results

31,226 results
Results by year
Filters applied: . Clear all
Page 1
Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview.
Wang LH, et al. Cell Physiol Biochem 2018 - Review. PMID 30562755 Free article.
Cancer is a disease caused by the accumulation of genetic and epigenetic changes in two types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. ...
Cancer is a disease caused by the accumulation of genetic and epigenetic changes in two types of genes: tumor suppressor genes …
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z, et al. Cancer Cell 2018. PMID 30537512 Free PMC article.
FAT1 loss led to marked elevations in CDK6, the suppression of which restored sensitivity to CDK4/6i. The induction of CDK6 was mediated by the Hippo pathway with accumulation of YAP and TAZ transcription factors on the CDK6 promoter. ...These findings uncover a tumor suppressor function of Hippo signaling in ER(+) breast cancer and establish FAT1 loss as a mechanism of resistance to CDK4/6i....
FAT1 loss led to marked elevations in CDK6, the suppression of which restored sensitivity to CDK4/6i. The induction of CDK6 was media …
Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.
Lee YR, et al. Science 2019. PMID 31097636
Activation of tumor suppressors for the treatment of human cancer has been a long sought, yet elusive, strategy. PTEN is a critical tumor suppressive phosphatase that is active in its dimer configuration at the plasma membrane. ...Either genetic ablation or pharmacological inhibition of WWP1 triggered PTEN reactivation and unleashed tumor suppressive activity. ...
Activation of tumor suppressors for the treatment of human cancer has been a long sought, yet elusive, strategy. PTEN is a cri …
Alteration of tumor suppressor BMP5 in sporadic colorectal cancer: a genomic and transcriptomic profiling based study.
Chen E, et al. Mol Cancer 2018. PMID 30572883 Free PMC article.
Notably, BMP5 negative expression and its prognostic value is uniquely significant in sCRC but not in other tumor types. Furthermore, BMP5 expression was positively correlated with E-cadherin in CRC patients and its dysregulation play a vital role in epithelial-mesenchymal transition (EMT), thus triggering tumor initiation and development. ...CONCLUSIONS: Our result support a novel concept that the importance of BMP5 in sCRC. The tumor suppressor role of BMP5 highlights its crucial role in CRC initiation and development....
Notably, BMP5 negative expression and its prognostic value is uniquely significant in sCRC but not in other tumor types. Furthermore, …
Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions.
Matsuhashi S, et al. Int J Mol Sci 2019 - Review. PMID 31075975 Free PMC article.
PDCD4 is a novel tumor suppressor to show multi-functions inhibiting cell growth, tumor invasion, metastasis, and inducing apoptosis. ...In this review, we focus on the suppression mechanisms of PDCD4 protein that is induced by the tumor promotors EGF and TPA, and in the inflammatory conditions. ...
PDCD4 is a novel tumor suppressor to show multi-functions inhibiting cell growth, tumor invasion, metastasis, and induc …
Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation.
Kim J, et al. Cancer Cell 2019. PMID 30712844 Free article.
The tumor suppressor p53 is somatically mutated in half of all human cancers. Paradoxically, the wild-type p53 (WTp53) is often retained in certain human cancers, such as hepatocarcinoma (HCC). We discovered a physiological and oncogenic role of WTp53 in suppressing pyruvate-driven oxidative phosphorylation by inducing PUMA. ...
The tumor suppressor p53 is somatically mutated in half of all human cancers. Paradoxically, the wild-type p53 (WTp53) is ofte …
UTX Mutations in Human Cancer
Wang L and Shilatifard A. Cancer Cell 2019 - Review. PMID 30753822 Free PMC article.
miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC
Jeon YJ, et al. Nat Commun 2018. PMID 30504895 Free PMC article.
The Tumor Suppressor Candidate 3 (TUSC3) at chromosome 8p22 known to be frequently deleted in cancer is often found to be deleted in advanced stage of solid tumors. ...Consequently, the alteration of UPRs and the suppressed p53-NM23H1/2 pathway by TUSC3 deficiency is ultimately responsible for enhancing metastatic potential of lung cancer. ...
The Tumor Suppressor Candidate 3 (TUSC3) at chromosome 8p22 known to be frequently deleted in cancer is often found to be dele …
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Teufel M, et al. Gastroenterology 2019. PMID 30738047 Free article.
METHODS: We obtained archived tumor tissues and baseline plasma samples from patients with HCC given regorafenib in the RESORCE trial. ...Next-generation sequencing analyses of tumor tissues revealed 49 variants in 27 oncogenes or tumor suppressor genes. Mutations in CTNNB1 were detected in 3 of 10 progressors and VEGFA amplification in 1 of 7 responders. ...
METHODS: We obtained archived tumor tissues and baseline plasma samples from patients with HCC given regorafenib in the RESORCE trial …
31,226 results
Jump to page
Feedback